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LETTERS
Telithromycin-
resistant
Streptococcus
pneumoniae
To the Editor: In recent years,
antimicrobial drug resistance in
Streptococcus pneumoniae has
increased worldwide and is a major
health concern.  Resistance to β-lac-
tams and macrolides, considered to be
first-line therapeutic agents, is partic-
ularly high in France and many Asian
countries (1–3). Resistance to new
fluoroquinolones is reported with
increasing frequency, which empha-
sizes the need for new effective drugs.
Telithromycin, the first member of
a new macrolide family, the ketolides,
has been developed to overcome
macrolide resistance. In vitro data
have shown that telithromycin
remains active against 98% to 100%
of erythromycin-resistant strains
(2,3). However, resistant mutants
have been isolated in vitro, and a few
poorly documented clinical failures
have been reported in the treatment of
pneumococcal infections. We report
the first isolation of telithromycin-
resistant S. pneumoniae from a blood
culture after therapy.
An 87-year-old woman was admit-
ted on March 28, 2004, to St Joseph
Hospital in Paris with typical upper
left lobar pneumonia, as inferred from
auscultatory results, radiologic find-
ings, and laboratory data: leukocytes
37,300 cells/µL, C-reactive protein
455 mg/L, and positive urinary pneu-
mococcal antigen (BinaxNOW,
Binax, Inc., Portland, ME, USA). She
was not febrile. She had been fol-
lowed for many years for chronic
obstructive pulmonary disease
(COPD), with acute exacerbation
only in 2001. At that time, she was
treated with the macrolide rox-
ithromycin, without bacteriologic
documentation, in addition to acetyl-
cysteine (3 × 200 mg/d) and
aerosolized terbutaline. On March 13,
her COPD was exacerbated. On
March 20, she visited her general
practitioner and received 800 mg/day
telithromycin for 5 days without
improvement. Because of a cutaneous
rash attributed to telithromycin, she
received 20 mg prednisolone. After
48 hours, she was admitted to St
Joseph Hospital because her respira-
tory syndrome was aggravated. A
blood culture drawn on admission
yielded a S. pneumoniae serotype 14
with decreased β-lactam susceptibili-
ty (MICs: penicillin G: 1 µg/mL;
amoxicillin: 0.75 µg/mL; cefotaxime:
0.5 µg/mL, as determined by Etest).
The strain was resistant to tetracy-
clines, cotrimoxazole, macrolides,
and lincosamides (erythromycin and
clindamycin MIC >32 µg/mL). The
MIC of telithromycin, performed on
Mueller-Hinton agar + 5% horse
blood by serial 2-fold dilution, was
equal to 2 µg/mL in air and 8 µg/mL
under CO2 (0.01–0.03 µg/mLfor con-
trol strains ATCC 49619 and 10 clini-
cal isolates, including 5 that were
MLSB [macrolide-lincosamide-strep-
togramin B]–resistant). The patient
was treated with 100 mg/kg/day intra-
venous amoxicillin and improved
within 48 hours. She was discharged
from the hospital 1 week later in good
condition but remained a healthy
carrier of resistant S. pneumoniae.
Resistance to macrolides has been
documented in France since our first
report in 1978 (4). In the last 10 years,
resistance has increased to ≈50% of
the strains in adults and >70% in chil-
dren, the highest in the Western
world. More than 98% of the strains
are of the MLSB phenotype, confer-
ring high-level resistance to
macrolides, lincosamides, and strep-
togramin B, in contrast to the situation
in the United States, where most
strains are of the mefE type (efflux),
which confers low-level resistance to
14- and 15-membered macrolides
only.  However, <2% of the
macrolide-resistant strains have a
decreased susceptibility to telithro-
mycin (2,3). Resistance to β-lactams
is also very frequent (≈50%), particu-
larly in erythromycin-resistant strains
(<90%); these figures explain why
macrolides may more likely select a
penicillin-resistant strain than most β-
lactams (5). 
Since resistance to telithromycin
was documented before ketolides
were introduced in clinical practice,
we cannot exclude the possibility that
the telithromycin- resistant strain was
selected in 2001, while our patient
was treated with roxithromycin.
The clinical impact of macrolide
resistance has been occasionally ques-
tioned since these antimicrobial
agents achieve high tissue and intra-
cellular levels. However, S. pneumo-
niae  is an extracellular bacterial
pathogen; well-designed clinical stud-
ies have documented the failure of
macrolides in treating high-level
resistant strains with an MLSB phe-
notype (6). After an 800-mg oral dose,
telithromycin achieves serum and
epithelial lining fluid concentrations
of 2.2 and 15 µg/mL, respectively,
yielding a free drug concentration of
0.7 µg/mLin the serum and 15 µg/mL
in the epithelial lining fluid. In an
excellent in vitro model, telithro-
mycin eradicated S. pneumoniae of
the mefE phenotype with MICs >0.25
and 1 µg/mL (7). The drug was not
effective against strains with MICs
2–8  µg/mL, as was seen in our
patient. When incubated under CO2,
MICs of macrolides increase by 1
dilution compared to the MIC in air,
against both susceptible and resistant
strains. With telithromycin, the MIC
increase is 2–6 dilutions but only for
macrolide-resistant strains (8). The
clinical impact of this finding is still
to be determined. This report empha-
sizes the need for routine testing of S.
pneumoniae isolates for resistance to
telithromycin.
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Integrated 
Human-Animal 
Disease
Surveillance 
To the Editor: Early identification
of zoonotic disease occurrence
through simultaneous monitoring of
human and animal disease surveil-
lance systems is critical to protect
health in both populations. We
assessed the surveillance and reporting
needs of a small but diverse group of
Michigan veterinarians by examining
their perspective of the current animal
disease reporting system, the system
enhancements desired, and their com-
puter and Internet accessibility. 
Developing systems that link
human and animal disease reporting
systems can help identify and facili-
tate a response to known and emerg-
ing zoonotic diseases. A system that
allows simultaneous electronic cap-
ture and assessment of human and
animal disease reports is being imple-
mented in Michigan. The system will
be based on the Michigan Disease
Surveillance System platform, a Web-
based human disease reporting system
implemented by the Michigan
Department of Community Health
(1,2).
To ensure an integrated system that
meets both human and veterinary
public health needs, we developed a
questionnaire for veterinarians to col-
lect information on the current animal
disease reporting system, system
enhancements that are desired, and
computer and Internet access capabil-
ities (University Human Research
Committee approved). In July 2003, a
total of 112 questionnaires was sent to
a convenience sample of Michigan
veterinarians who represent a variety
of practice types and sizes, participate
in organized veterinary medicine and
academia, and would be motivated to
participate in system development. Of
the 112 questionnaires, 84 (75%) were
completed. Of 79 practices represent-
ed, 19 (24%) treated companion ani-
mals, 15 (19%) treated equids, 4 (5%)
treated food animals (dairy, beef,
small ruminant, poultry, or swine), 32
(41%) treated a variety of animals (no
patient type >75%), 4 (5%) treated
zoo animals, and 5 (6%) veterinarians
were not in clinical practice. 
Of 81 respondents, 75 (93%) indi-
cated that they were aware of the
Michigan reportable animal disease
list. Yet, 37 (47%) of 79 respondents
have reported no cases and 32 (41%)
of 79 have reported 1 to 5 cases annu-
ally. Furthermore, only 19 (25%) of
76 respondents reported that their
clients might have confidentiality
issues that could impede disease
reporting. Therefore, it will be impor-
tant to continue educating veterinari-
ans to ensure that suspected disease
cases are reported as well as con-
firmed cases, which may have been
reported by the laboratory also. 
Positive feedback was received
regarding the current animal disease
reporting system. Respondents evalu-
ated the availability of a published list
of reportable diseases (68 [89%] of
76) and the availability and quality of
laboratory testing and disease confir-
mation (57 [75%] of 76) as Strongly
Like/Like (Scale = Strongly Dislike,
Dislike, No Opinion, Like, Strongly
Like). However, case submission
feedback may need to be assessed as
only 34 (45%) of 76 respondents eval-
uated this service as Strongly
Like/Like and 13 (17%) of 76 evalu-
ated it as Strongly Dislike/Dislike.
Of 73 respondents, 68 (93%)
reported that routinely published ani-
mal disease surveillance data would
be beneficial for themselves or their
clients. Of 55 respondents, 24 (44%)
indicated that these data would be
used to increase disease awareness
and 23 (42%) indicated the data
would be used for risk assessment and
prevention planning. Outbreak alert
information, easy access to regulatory
requirements, and animal disease
information were also desired.
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